{"disease":{"id":"seizures-tonic-clonic","name":"seizures tonic clonic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03059329","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","phase":"","overall_status":"COMPLETED","enrollment_count":3809,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT01463306","title":"A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT03059381","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","phase":"","overall_status":"COMPLETED","enrollment_count":519,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT04252846","title":"A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Eisai Limited","has_results":false},{"nct_id":"NCT04770337","title":"Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Neuroelectrics Corporation","has_results":false},{"nct_id":"NCT06657378","title":"A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures","phase":"","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT03288129","title":"Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT03443388","title":"Novel Helmet Design in Patients With Seizures","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Michael A. Gelfand, MD, PhD","has_results":true},{"nct_id":"NCT03283748","title":"Detection of Motor Seizures Using WBAN","phase":"NA","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Mohawk College","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}